Carcinoid Tumor Market Overview
Carcinoid syndrome is the aftermath which occurs after carcinoid tumors. Signs of the syndrome include unexplained weight gain, sweating, fast heartbeat, intestinal bleeding, vasoconstriction, and shortness of breath. A combination of palliative and supportive care is required for controlling the syndrome. Market Research Future (MRFR) outlines various trends and opportunities in the global carcinoid syndrome management market which estimate an accurate market valuation.
The global carcinoid tumour market is estimated to show significant growth with a CAGR of 10.5% during the forecast period 2022-2030.
Paucity of approved drugs and vaccines for controlling the disease can be the only restraining factor in the market.Factors such as the rising incidence of carcinoid tumours, growth in medical diagnostic technology such as endoscopy ultrasonography, availability of favourable reimbursement and insurance policies are accelerating the Carcinoid Tumor Market growth. Moreover drug treatments associated with carcinoid tumour are likely to get orphan drug status, government initiatives of setting high price for orphan drugs will generate more revenue for pharma companies, thus fuelling up the market growth. Whereas, high expense of this the diagnosis, lack of targeted treatments for the disease, misdiagnosis of the diseases as symptoms are very confusing and unavailability of advanced diagnostic methods in middle income countries are hindering the market growth.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/4813
KryPlayers
Novartis AG (Europe), Ingelheim GmbH (Europe), AVEO Pharmaceuticals, Inc. (U.S.), Chiasma, Inc. (U.S.), Amgen Inc. (U.S.), Boehringer Aegis Therapeutics, LLC (U.S.), CRINETICS PHARMACEUTICALS (U.S.), Delcath Systems Inc. (U.S.), Exelixis, Inc. (U.S.), and others., are key market players in global carcinoid tumour market and are profiled in MRFR Analysis.
Carcinoid Tumour Market Segmentation
The carcinoid syndrome management market is segmented by organs affected by the disease, treatment, and end-user.
By organs affected by the disease, it is segmented into liver, pancreas, stomach, colon, appendix, lungs, rectum, small intestine, and others. The small intestine segment accounted for 40% share followed by rectum at 14% share in 2017.
By treatment, it is segmented into hepatic artery embolization agents, biological therapy, and chemotherapy. Chemotherapy is projected to gain a large market share due to being the first line of treatment for cancers. Bu hepatic artery embolization agents are gaining traction and may contribute to overall market revenue. This can be attributed to awareness of carcinoid syndrome among patients.
By end-user, it is segmented into cancer institutions and treatment centers, clinics, hospitals, and others. Cancer institutions and treatment centers can vouch for the largest market share due to inflow of sufficient capital for hosting patients with serious conditions. Pharmacies attached to these centers provide medicines and drugs to alleviate pain can bode well for the market. On the other hand, hospitals are likely to command a significant market share in the coming years
Carcinoid Tumour Market- competitive Analysis
Novartis headquartered in Switzerland has been solving healthcare challenges with its innovative solutions for more than half a century. It has several chemotherapy drugs in its portfolio. In 2016, Novartis announced approval of Afinitor by U.S. FDA, and it is the first treatment approved for progressive, non-functional carcinoid tumour of lung origin.
Amgen Inc. with its eminent team of RD professionals has been a top pharmaceutical with a huge global presence since 1979. AMG-479 Ganitumab is the brainchild of Amgen which has potential to treat carcinoid tumours. It has completed phase II clinical trial successfully.
Carcinoid Tumour Market- Regional Analysis
Asia Pacific (APAC), the Americas, the Middle East Africa (MEA), and Europe are regions covered in the global carcinoid syndrome management market report.
The Americas accounted for the lion’s share of the market due to availability of drugs and screening tests required for early identification of the disease. Developed healthcare sector and high healthcare budget of countries with the introduction of people-friendly policies can drive the regional market growth.
The APAC region is presumed to exhibit a robust growth rate during the forecast timespan
The MEA region is expected to control the lowest market share due to presence of economies with uncertain policies and underdeveloped healthcare infrastructure.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/carcinoid-tumor-market-4813
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
